Atara Biotherapeutics Inc $ 18.44 0.11 (0.6%)
Volume:
478,052
Avg Vol (1m):
988,831
Market Cap $:
1.53 Bil
Enterprise Value $:
1.22 Bil
P/E (TTM):
0.00
P/B:
4.23
Financial Strength | 5/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 24.92 | ||
Debt-to-Equity | 0.04 | ||
Debt-to-EBITDA | -0.04 | ||
Piotroski F-Score | 2 | ||
WACC vs ROIC |
Profitability Rank | 1/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
ROE % | -95.11 | ||
ROA % | -82.52 | ||
ROC (Joel Greenblatt) % | -455.37 | ||
3-Year EBITDA Growth Rate | -26 | ||
3-Year EPS without NRI Growth Rate | -27.3 |
ATRA
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 4.23 | ||
EV-to-EBIT | -3.96 | ||
EV-to-EBITDA | -4.07 | ||
Current Ratio | 9.41 | ||
Quick Ratio | 9.41 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -25.2 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 4.23 | ||
Earnings Yield (Greenblatt) % | -25.25 |